Nobias Therapeutics
- Biotech or pharma, therapeutic R&D
Clinical-stage company developing novel small molecule therapeutics for rare diseases. Lead asset is a small molecule mGluR modulator with positive Ph 2 data in 22q11DS (lead indication).
June 16-19, 2025
Boston Convention & Exhibition Center
Clinical-stage company developing novel small molecule therapeutics for rare diseases. Lead asset is a small molecule mGluR modulator with positive Ph 2 data in 22q11DS (lead indication).